Breaking News, Trials & Filings

Eylea Apprved in Japan

Newest market after U.S., EC

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Regeneron Pharmaceuticals‘ Eylea (aflibercept) Injection has received approval for the treatment of Macular Edema Following Central Retinal Vein Occlusion (CRVO) from the Japanese Ministry of Health, Labour and Welfare (MHLW). Eylea was approved in the U.S. for the treatment of neovascular (wet) Age-related Macular Degeneration (AMD) in November 2011 and for Macular Edema following Central Retinal Vein Occlusion (CRVO) in September 2012. Eylea has also been approved in the European Union ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters